Big Data for Tiny Patients: A Precision Medicine Approach to Bronchopulmonary Dysplasia

Area of Science:

• Neonatology
• Pulmonary Medicine
• Genomics

Background:

• Bronchopulmonary dysplasia (BPD) is the most frequent chronic lung condition in extremely premature infants.
• Current BPD treatments are largely ineffective, and prediction of affected neonates remains a clinical challenge.
• Understanding the molecular basis of arrested lung development in BPD is crucial.

Purpose of the Study:

• To review the application of omics technologies for BPD prediction and patient stratification.
• To highlight the potential of precision medicine in identifying BPD biomarkers and therapeutic targets.
• To discuss emerging multi-omics programs for BPD research.

Main Methods:

• Review of current literature on omics studies (genomics, transcriptomics, etc.) in BPD.
• Analysis of how omics data can aid in predicting BPD development.
• Examination of precision medicine strategies for BPD.

Main Results:

• Omics approaches are increasingly used to gain insights into BPD pathogenesis.
• These technologies show promise for improving early prediction and classifying patient subgroups.
• Biomarkers and potential therapeutic pathways are being identified through omics data.

Conclusions:

• Integrating omics data is essential for advancing our understanding of BPD.
• Precision medicine, powered by multi-omics, offers a path toward better BPD prediction and treatment.
• Novel research programs are leveraging multi-omics to tackle BPD pathogenesis.